Relating In Vitro Neutralization Level and Protection in the CVnCoV (CUREVAC) Trial
Authors:
Open Access
- 1 February 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 75 (1) , e878-e879
Abstract
The vaccine candidate CVnCoV (CUREVAC) showed surprisingly low efficacy in a recent phase 3 trial compared with other messenger RNA (mRNA) vaccines. Here we show that the low efficacy follows from the dose used and the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and is predicted by the neutralizing antibody response induced by the vaccine.Keywords
All Related Versions
Funding Information
- Australian government Medical Research Future Fund (GNT2002073, MRF2005544, MRF2005760, MRF2007221)
- NHMRC (GNT1149990)
This publication has 9 references indexed in Scilit:
- Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysisThe Lancet Microbe, 2021
- Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2Wiener klinische Wochenschrift, 2021
- Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 VariantsNew England Journal of Medicine, 2021
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infectionNature Medicine, 2021
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineNew England Journal of Medicine, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine CandidatesNew England Journal of Medicine, 2020
- An mRNA Vaccine against SARS-CoV-2 — Preliminary ReportNew England Journal of Medicine, 2020
- Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNAImmunity, 2005